FDA Agrees to Speed Review of Ariad Drug

The FDA has agreed to an accelerated review of Ariad Pharmaceuticals' (NAS: ARIA) leukemia drug ponatinib, the company announced Wednesday. The FDA has established an action date of March 27, the company said.

The FDA accepted Ariad's request to launch a "priority review," which the FDA uses to shorten the review time for drugs that could provide significant improvements in treatment of diseases. Ponatinib is aimed at treating chronic myeloid leukemia and acute lymphoblastic leukemia, doing so by inhibiting an abnormality known as BCR-ABL.

Ponatinib will face competition from other leukemia drugs on the market, including products from Novartis (NYS: NVS) and Bristol-Myers Squibb (NYS: BMY) . Competition and questions  about approval spurred an analyst at Oppenheimer & Co. to downgrade Ariad earlier this week from "outperform" to "perform." The analyst also raised his price target to $23.

The Boston Globe quoted CEO Harvey Berger as saying: "We're launch-ready as we stand here today. Whenever the approval comes, we have the sales and distribution force, the manufacturing people, the medical liaisons, all the people we need to commercialize successfully."

The article FDA Agrees to Speed Review of Ariad Drug originally appeared on Fool.com.

Dan Carroll has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.